China Approves Two Sanofi Drugs for Rare Blood Disorders
China’s National Medical Products Administration (NMPA) has approved two innovative Sanofi therapies—Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired…
Read More...
Read More...
